- The transaction further enhances market access to the third largest pharmaceutical market
- Fuji Pharma brings a wealth of industry experience in Japan and an excellent women’s healthcare portfolio
- Lotus contributes rich experience of developing complex oral oncology products and access to APAC markets
- Both parties are committed to further portfolio expansion to better serve more customers across Asia
Lotus Pharmaceutical Co., Ltd (“Lotus”, TPEX ticker: 1795) and Fuji Pharma Co. Ltd. (“Fuji”, TSE First Section ticker: 4554), today announced execution of capital and business collaboration agreements. Under the terms of the cash-natural capital collaboration Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
The transaction is designed to further strengthen Lotus and Fuji’s commercial platform in Japan and other key Asian pharmaceutical markets, to explore cross-selling opportunities, realizing synergies in manufacturing and to jointly invest in the development of specialty products for the region.
Commenting on the transaction, Robert Wessman, Chairman of Lotus, said:
Hirofumi Imai, Chairman of Fuji Pharma, said: